my personal edition > psychiatry other > news


  E-Mail this DGNews to a colleague

DGNews

Adderall XR - FDA Approves Three New Strengths

BASINGSTOKE, ENGLAND -- May 23, 2002 -- Shire Pharmaceuticals Group plc announces that it has received Food and Drug Administration (FDA) approval for three further strengths of Adderall XR™ (mixed salts of a single entity amphetamine product), its once a day treatment for Attention Deficit Hyperactivity Disorder (ADHD).

The newly approved 5, 15 and 25mg capsules complement the existing 10, 20 and 30mg capsules to provide doctors with significant flexibility to individually tailor the dosing to each patient's needs. With this wider range now available patients converting from Adderall™ to Adderall XR will be able to change more easily from their existing daily dose of Adderall directly to the convenient and effective once a day Adderall XR capsule.

Bill Nuerge, President and CEO, Shire US Inc. said: "The availability of a full complement of strengths for Adderall XR furthers our goal to provide doctors and their ADHD patients with effective treatments that suit their needs and lifestyles. We have continuous commitments to a long-term presence in this important expanding disease area which includes work to extend the indications for ADDERAL XR together with developing new non- scheduled ADHD treatments."

Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international specialty pharmaceutical company with a strategic focus on three therapeutic areas -- central nervous system disorders (CNS), oncology and anti-infectives. Shire also has two platform technologies: advanced drug delivery and Biologics. Shire's core strategy is based on research and development combined with in-licensing and a focus on eight key pharmaceutical markets. For further information on Shire, please visit the company's website: http://www.shire.com

The "Safe Harbour" Statement Under The Private Securities Litigation Reform Act Of 1995.

The statements in this press release that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event that such risks or uncertainties materialise, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development and commercialisation, the impact of competitive products, patents, government regulation and approval, and other risks and uncertainties detailed from time to time in periodic reports produced by Shire, including the Annual Report filed on Form 10K by Shire with the Securities and Exchange Commission.


SOURCE: Shire Pharmaceuticals Group plc

E-Mail this DGNews to a colleague

To print, use this version